Fusion Glycoprotein Vaccine for Human Metapneumovirus

Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5-15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised. Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (“F protein”) stabilized in a prefusion conformation.

Stabilizing this prefusion conformation of the F protein reveals an immunodominant site which makes it an ideal vaccine immunogen. The prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404.

Potential Commercial Applications: Competitive Advantages:
  • Vaccine for prevention of human metapneumovirus infection
  • No human metapneumovirus vaccine is currently available


Peter Kwong (NIAID)  ➽ more inventions...

Michael Joyce (NIAID)  ➽ more inventions...

Peter Collins (NIAID)  ➽ more inventions...

Ursula Buchholz (NIAID)  ➽ more inventions...

Guillaume Stewart-Jones (NIAID)  ➽ more inventions...

Baoshan Zhang (NIAID)  ➽ more inventions...

Yongping Yang (NIAID)  ➽ more inventions...

Davide Corti

Antonio Lanzavecchia

Intellectual Property:
US Pat: 10,420,834 issued 2019-09-24
PCT Application No. PCT/IB2015/059991 filed on 2015-12-24
US Application No. 15/539,640 filed on 2017-06-23
EP Application No. 15831073.0 filed on 2015-12-24
US Application No. 16/578,748 filed on 2019-09-23

Licensing Contact:
Carol Salata, Ph.D.
Email: csalata@mail.nih.gov
Phone: 240-627-3727

OTT Reference No: E-260-2014-0
Updated: Oct 29, 2018